S'abonner

Comparison of outcomes of white versus black patients hospitalized with heart failure and preserved ejection fraction - 26/08/11

Doi : 10.1016/j.amjcard.2004.06.054 
Ildiko Agoston, MD a, Craig S. Cameron, MD b, David Yao, MD c, Ariel DeLa Rosa, MD d, Douglas L. Mann, MD d, e, Anita Deswal, MD, MPH d, e,
a Division of Cardiology, University of Texas Medical Branch, Galveston, Texas, USA 
b Division of Cardiology, Baylor University Medical Center, Dallas, Texas, USA 
c Department of Medicine 
d Section of Cardiology, Baylor College of Medicine, Dallas, Texas, USA 
e Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA 

*Address for reprints: Anita Deswal, MD, MPH, Michael E. DeBakey Veterans Administration Medical Center (152), 2002 Holcombe Boulevard, Houston, Texas

Résumé

Black patients who have heart failure (HF) may have a larger proportion of HF with preserved ejection fraction (PEF) than white patients because of the greater prevalence and severity of hypertension and left ventricular hypertrophy in blacks. However, studies have not systematically evaluated differences by race in patients who have HF-PEF compared with those who have systolic HF (SHF). Therefore, we examined baseline characteristics and long-term outcomes in patients who had HF-PEF compared with those who had SHF, with an emphasis on variation by race, in a biracial cohort of patients treated within the Veterans Health Administration health care system. In a cohort of 448 patients (192 blacks and 256 whites) hospitalized with HF, 27% had HF-PEF. The proportion of HF-PEF was similar in black (25%) and white (29%) patients (p = 0.4). Among patients who had SHF, black patients were younger, had lower prevalences of atrial fibrillation and diabetes, and had less co-morbidities than white patients, whereas there were no significant differences in these variables by race in patients who had HF-PEF. However, among patients who had SHF or HF-PEF, blacks had a lower prevalence of coronary disease, higher systolic and diastolic blood pressures, and higher serum levels of creatinine than white patients. In addition, mortality and readmission rates for HF did not differ by race among patients who had HF-PEF. Overall, patients who had HF-PEF had a high morbidity rate (30% patients were readmitted for HF in ≤6 months) and a high mortality rate (44% at 3 years), despite the use of angiotensin-converting enzyme inhibitors by 66% of patients at discharge. This underscores the importance of evaluating other agents for the treatment of patients who have HF-PEF.

Le texte complet de cet article est disponible en PDF.

Plan


 This work was supported in part by research funds from Veterans Affairs HSR&D grants IIR 02-082-1. Dr. Deswal is recipient of an Advanced Clinical Research Career Development Award (CRCD 712A) from the Veterans Affairs Cooperative Studies Program.


© 2004  Excerpta Medica Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 94 - N° 8

P. 1003-1007 - octobre 2004 Retour au numéro
Article précédent Article précédent
  • Gender differences in the value of ST-segment depression during adenosine stress testing
  • Martha Gulati, Pravin Pratap, Preeti Kansal, James E. Calvin, Robert C. Hendel
| Article suivant Article suivant
  • Prognostic significance of newly acquired bundle branch block after aortic valve replacement
  • Ziad El-Khally, Bernard Thibault, Cezar Staniloae, Pierre Theroux, Marc Dubuc, Denis Roy, Peter Guerra, Laurent Macle, Mario Talajic

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.